Molecular control of CD4 T cell ability to help B cells

CD4 T 细胞帮助 B 细胞能力的分子控制

基本信息

  • 批准号:
    10357910
  • 负责人:
  • 金额:
    $ 11.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-03-01 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract: This proposal details a five-year research and training plan with a scientific focus on a newly discovered population of T cells, termed `T peripheral helper' (Tph) cells, that is markedly expanded in the joints of patients with rheumatoid arthritis. The candidate led a study that identified and defined this CD4+ T cell subset (Rao et al, Nature, 2017). Tph cells display a unique capacity to infiltrate inflamed tissues and drive B cell responses within the tissue. The long-term objective of the proposed study is to understand signals that regulate the development and function of Tph cells in the hope of discovering pathways that can be manipulated therapeutically to treat autoimmune diseases. The specific aims proposed here utilize three complementary approaches to evaluate the regulation of Tph cells. Aim 1 will determine conditions that drive human T cell differentiation towards a Tph cell phenotype. Aim 2 interrogates the control of Tph cell function by 3 compelling transcriptional regulators that are overexpressed in Tph cells. Aim 3 evaluates the developmental relationship of Tph cells in RA synovial tissue samples with other synovial T cell populations, including T follicular helper cells. Using a combination of mechanistic studies, patient-derived samples, and cutting-edge technologies, this study will provide the candidate with new training in several key aspects of human translational immunology. The candidate's immediate career development goals are to gain experience with bioinformatic and biostatistical analyses, interpretation of transcriptomic data, genomic manipulation of primary human cells, and scientific communication. A specific career development plan is described by both the candidate and the mentors: Dr. Michael Brenner MD, an expert in lymphocyte biology and synovial inflammation, and Dr. Soumya Raychaudhuri MD PhD, an expert in bioinformatics, capitalizing on the powerful resources at Brigham and Women's Hospital and Harvard Medical School. The candidate's long-term career goal is to attain a tenure- track faculty position pursuing research that integrates high-dimensional analyses of patient samples with detailed mechanistic analyses to develop new methods to diagnose and treat rheumatic diseases.
项目概要/摘要: 该提案详细介绍了一项为期五年的研究和培训计划,其科学重点是新发现的 一群T细胞,称为“T外周辅助”(Tph)细胞,在患者关节中显著扩增 风湿性关节炎这位候选人领导了一项研究,确定并定义了这种CD 4 + T细胞亚群(Rao et 等人,Nature,2017)。Tph细胞显示出独特的能力,渗透发炎组织和驱动B细胞反应 在组织内。这项研究的长期目标是了解调节神经元的信号。 Tph细胞的发育和功能,希望发现可以操纵的途径, 治疗自身免疫性疾病。 这里提出的具体目标利用三种互补的方法来评估Tph的调节 细胞目的1将确定驱动人T细胞向Tph细胞表型分化的条件。目的 2询问Tph细胞功能的控制由3个引人注目的转录调节因子, 在Tph细胞中。目的3评价类风湿关节炎滑膜组织中Tph细胞的发育关系, 其他滑膜T细胞群,包括T滤泡辅助细胞。 使用机制研究,患者来源的样本和尖端技术的组合,这项研究 将在人类翻译免疫学的几个关键方面为候选人提供新的培训。的 候选人的直接职业发展目标是获得生物信息学和生物统计学方面的经验 转录组学数据的分析、解释、原代人类细胞的基因组操作,以及科学 通信一个具体的职业发展计划是由候选人和导师描述:博士。 Michael Brenner医学博士,淋巴细胞生物学和滑膜炎症专家,Soumya博士 Raychaudhuri医学博士,生物信息学专家,利用布里格姆的强大资源, 妇女医院和哈佛医学院。候选人的长期职业目标是获得终身职位- 跟踪教师职位追求的研究,整合患者样本的高维分析, 详细的机制分析,以开发新的方法来诊断和治疗风湿性疾病。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Identification of T Peripheral Helper (Tph) Cells.
外周辅助 T (Tph) 细胞的鉴定。
T Cells That Help B Cells in Chronically Inflamed Tissues.
  • DOI:
    10.3389/fimmu.2018.01924
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Rao DA
  • 通讯作者:
    Rao DA
Editorial: Lymphocyte Highs and Lows With Baricitinib.
社论:Baricitinib 的淋巴细胞高点和低点。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Deepak Angara Rao其他文献

Deepak Angara Rao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Deepak Angara Rao', 18)}}的其他基金

Regulation of T helper cell functions by aryl hydrocarbon receptor
芳烃受体对 T 辅助细胞功能的调节
  • 批准号:
    10179018
  • 财政年份:
    2021
  • 资助金额:
    $ 11.64万
  • 项目类别:
Regulation of T helper cell functions by aryl hydrocarbon receptor
芳烃受体对 T 辅助细胞功能的调节
  • 批准号:
    10596640
  • 财政年份:
    2021
  • 资助金额:
    $ 11.64万
  • 项目类别:
Post-transcriptional Regulation of IL-21 in Human T Cells
人类 T 细胞中 IL-21 的转录后调控
  • 批准号:
    10404915
  • 财政年份:
    2021
  • 资助金额:
    $ 11.64万
  • 项目类别:
Regulation of T helper cell functions by aryl hydrocarbon receptor
芳烃受体对 T 辅助细胞功能的调节
  • 批准号:
    10407049
  • 财政年份:
    2021
  • 资助金额:
    $ 11.64万
  • 项目类别:

相似海外基金

Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
  • 批准号:
    EP/Y031091/1
  • 财政年份:
    2024
  • 资助金额:
    $ 11.64万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 11.64万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 11.64万
  • 项目类别:
    Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
  • 批准号:
    10715807
  • 财政年份:
    2023
  • 资助金额:
    $ 11.64万
  • 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
  • 批准号:
    MR/Y003667/1
  • 财政年份:
    2023
  • 资助金额:
    $ 11.64万
  • 项目类别:
    Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
  • 批准号:
    10740682
  • 财政年份:
    2023
  • 资助金额:
    $ 11.64万
  • 项目类别:
Sjogren's Syndrome Pathogenic Autoantibodies
干燥综合征致病性自身抗体
  • 批准号:
    10854472
  • 财政年份:
    2023
  • 资助金额:
    $ 11.64万
  • 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
  • 批准号:
    487849
  • 财政年份:
    2023
  • 资助金额:
    $ 11.64万
  • 项目类别:
    Operating Grants
Analysis of pathogenesis associated with mutation of complement associated gene and autoantibodies in development/progression of C3 nephropathy.
补体相关基因突变和自身抗体在C3肾病发生/进展中的发病机制分析。
  • 批准号:
    22K08309
  • 财政年份:
    2022
  • 资助金额:
    $ 11.64万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
  • 批准号:
    10481071
  • 财政年份:
    2022
  • 资助金额:
    $ 11.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了